# Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

> **NCT04106843** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Locally Advanced Adrenal Gland Pheochromocytoma
- Locally Advanced Paraganglioma
- Metastatic Adrenal Gland Pheochromocytoma
- Metastatic Paraganglioma
- Metastatic Parathyroid Gland Carcinoma
- Pituitary Gland Carcinoma
- Somatostatin Receptor Positive
- Stage III Thyroid Gland Medullary Carcinoma AJCC v8
- Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
- Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8
- Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8
- Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
- Unresectable Adrenal Gland Pheochromocytoma
- Unresectable Paraganglioma

## Interventions

- **DRUG:** Lutetium Lu 177 Dotatate

## Key facts

- **NCT ID:** NCT04106843
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-13
- **Primary completion:** 2020-09-03
- **Final completion:** 2020-09-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No Participants Registered
- **Last updated:** 2020-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106843, "Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04106843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*